NDAINTRACAVITARY, INTRAVENOUS, INTRAVESICALPOWDER
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
4/8 — Partial
TEPADINA (thiotepa) by Adienne Pharma and Biotech is alkylating activity [moa]. First approved in 2017.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEPADINA (thiotepa) is an alkylating agent approved in 2017 for intracavitary, intravenous, and intravesical administration as a powder formulation. It works by forming covalent bonds with DNA, disrupting tumor cell replication and inducing apoptosis. The drug is indicated for patients requiring cytoreductive therapy in hematologic malignancies and solid tumors.
Peak10.7 years to LOE
At peak lifecycle with stable market position, the brand likely operates with a lean, specialized team focused on maintaining market share in niche oncology segments.
Mechanism of Action
Alkylating Activity
Pharmacologic Class:
Alkylating Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
Started Dec 2006
1 enrolled
Graft Versus Host DiseaseLeukemiaMyelodysplastic Syndromes
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
Started Mar 2005
37 enrolled
Lymphoma
Career Relevance
TEPADINA offers a career opportunity in a mature, niche oncology franchise where stability and deep therapeutic expertise are valued over high-growth dynamics. Professionals on this team develop specialized knowledge in alkylating therapy, rare tumor management, and complex drug delivery systems.
Worked on TEPADINA at Adienne Pharma and Biotech? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.